The Hymenoptera venom study III: Safety of venom immunotherapy
One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenan...
Saved in:
Published in | Journal of allergy and clinical immunology Vol. 86; no. 5; pp. 775 - 780 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Mosby, Inc
01.11.1990
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 μg and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 μg and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe. |
---|---|
AbstractList | One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 μg and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 μg and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe. One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe. One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe. One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 mu g and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe. |
Author | Olive, Emory S. Bukantz, Samuel C. Lockey, Richard F. Turkeltaub, Paul C. Hubbard, James M. Baird-Warren, Irene A. |
Author_xml | – sequence: 1 givenname: Richard F. surname: Lockey fullname: Lockey, Richard F. organization: Tampa, Fla., USA – sequence: 2 givenname: Paul C. surname: Turkeltaub fullname: Turkeltaub, Paul C. organization: Tampa, Fla., USA – sequence: 3 givenname: Emory S. surname: Olive fullname: Olive, Emory S. organization: Tampa, Fla., USA – sequence: 4 givenname: James M. surname: Hubbard fullname: Hubbard, James M. organization: Tampa, Fla., USA – sequence: 5 givenname: Irene A. surname: Baird-Warren fullname: Baird-Warren, Irene A. organization: Tampa, Fla., USA – sequence: 6 givenname: Samuel C. surname: Bukantz fullname: Bukantz, Samuel C. organization: Tampa, Fla., USA |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19665022$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/2229842$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtPwkAUhWeBQUB_Akk3Gl1U59GZzrjQGKJCQuICXE-mM7ehhrbYaUn67y3QsGV1H-fLzc05YzQoygIQmhL8RDARzyuMFQlFHKkHzB8lJpKG0QCNzutrNPb-F3czk2qIhpRSJSM6Qq_rDQTzNoei3NVQmWDfdXng68a1wWKxeAlWJoW6Dcq0l7I8b4qy3nTwrr1BV6nZerjt6wT9fH6sZ_Nw-f21mL0vQ6BC1aEDJpIkxgyk4swY65ylAIkRKlFpFNEUp4YbEhPKnFIRcVYQFuMEE-COMzZB96e7u6r8a8DXOs-8he3WFFA2XkuMperuXAQjpYjkUlwECZfx4Z0OnPZgk-Tg9K7KclO1urew0-963XhrtmllCpv5M0aUEBzTA_d24qDzaZ9Bpb3NoLDgsgpsrV2ZaYL1IU99zFMfgtOY62OeOmL_0GuTzg |
CODEN | JACIBY |
ContentType | Journal Article |
Copyright | 1990 Mosby-Year Book, Inc. 1991 INIST-CNRS |
Copyright_xml | – notice: 1990 Mosby-Year Book, Inc. – notice: 1991 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM 7T5 H94 7S9 L.6 7X8 |
DOI | 10.1016/S0091-6749(05)80182-4 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 780 |
ExternalDocumentID | 2229842 19665022 S0091674905801824 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACPRK ACRLP ACRPL ADBBV ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AFFNX AFJKZ AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~KM AAFWJ AAYWO ACIEU ACVFH ADCNI ADXHL AEUPX AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP APXCP EFKBS IQODW 3V. 7RV 7X7 8C1 AFKRA AFKWA AJOXV AMFUW BBNVY BENPR BHPHI CGR CUY CVF ECM EIF HCIFZ M2O M7P NPM PKN 7T5 H94 7S9 L.6 7X8 |
ID | FETCH-LOGICAL-e269t-de36bb703e8953aacddc2eeba69b9f442f0fa5a17123d9941dc61370b01e5d533 |
ISSN | 0091-6749 |
IngestDate | Fri Jul 11 11:01:36 EDT 2025 Fri Jul 11 08:17:43 EDT 2025 Fri Jul 11 04:32:16 EDT 2025 Wed Feb 19 02:33:51 EST 2025 Mon Jul 21 09:15:57 EDT 2025 Sun Apr 06 06:53:01 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Allergy Immunopathology Arthropoda Insecta Immunotherapy Venom Invertebrata Hymenoptera Allergen Skin test |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-e269t-de36bb703e8953aacddc2eeba69b9f442f0fa5a17123d9941dc61370b01e5d533 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 2229842 |
PQID | 15877123 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_80089442 proquest_miscellaneous_49918586 proquest_miscellaneous_15877123 pubmed_primary_2229842 pascalfrancis_primary_19665022 elsevier_sciencedirect_doi_10_1016_S0091_6749_05_80182_4 |
PublicationCentury | 1900 |
PublicationDate | 1990-Nov |
PublicationDateYYYYMMDD | 1990-11-01 |
PublicationDate_xml | – month: 11 year: 1990 text: 1990-Nov |
PublicationDecade | 1990 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Journal of allergy and clinical immunology |
PublicationTitleAlternate | J Allergy Clin Immunol |
PublicationYear | 1990 |
Publisher | Mosby, Inc Elsevier |
Publisher_xml | – name: Mosby, Inc – name: Elsevier |
References | Lockey, Benedict, Turkeltaub, Bukantz (bib10) 1987; 79 Package Insert-Pharmalgen: freeze-dried Hymenoptera venom/venom protein allergenic extracts. Directions for use. Pharmacia Diagnostics, Piscataway, N.J. Golden, Valentine, Kagey-Sobotka (bib7) 1980; 92 Reisman (bib9) 1988; 671 Bousquet, Muller, Dreborg (bib3) 1987; 42 Package Insert-Albany: instructions and dosage schedule for allergenic extracts Hymenoptera venom products. Hollister-Stier Laboratories Spokane, Wash. Van Metre, Adkinson, Amodio (bib8) 1982; 69 Golden, Valentine (bib6) 1986 Lockey, Turkeltaub, Baird-Warren (bib1) 1988; 82 Committee on Safety of Medicines Update (bib11) 1986; 293 Lockey, Turkeltaub, Olive, Baird-Warren, Olive, Bukantz (bib2) 1989; 84 |
References_xml | – volume: 92 start-page: 620 year: 1980 ident: bib7 article-title: Regimens of Hymenoptera venom immunotherapy publication-title: Ann Intern Med – volume: 671 start-page: 383 year: 1988 end-page: 387 ident: bib9 article-title: Late onset reactions following venom immunotherapy and venom skin tests publication-title: Ann Allergy – reference: Package Insert-Pharmalgen: freeze-dried Hymenoptera venom/venom protein allergenic extracts. Directions for use. Pharmacia Diagnostics, Piscataway, N.J. – reference: Package Insert-Albany: instructions and dosage schedule for allergenic extracts Hymenoptera venom products. Hollister-Stier Laboratories Spokane, Wash. – volume: 42 start-page: 401 year: 1987 end-page: 413 ident: bib3 article-title: Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology publication-title: Allergy – volume: 293 start-page: 948 year: 1986 ident: bib11 article-title: Desensitising vaccines publication-title: Br Med J – volume: 79 start-page: 660 year: 1987 end-page: 677 ident: bib10 article-title: Fatalities from immunotherapy (IT) and skin testing (ST) publication-title: J Allergy Clin Immunol – volume: 82 start-page: 370 year: 1988 end-page: 381 ident: bib1 article-title: The Hymenoptera venom study I, 1979–1982: demographics and history-sting data publication-title: J Allergy Clin Immunol – volume: 69 start-page: 181 year: 1982 ident: bib8 article-title: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever publication-title: J Allergy Clin Immunol – volume: 84 start-page: 967 year: 1989 end-page: 974 ident: bib2 article-title: The Hymenoptera venom study II: skin test results and safety of venom skin testing publication-title: J Allergy Clin Immunol – start-page: 57 year: 1986 end-page: 62 ident: bib6 article-title: Immunotherapy with insect venoms: techniques, schedules, adverse reactions publication-title: Monograph on insect allergy |
SSID | ssj0009389 |
Score | 1.7427915 |
Snippet | One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95... One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). This study, the largest of its kind... |
SourceID | proquest pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 775 |
SubjectTerms | administration & dosage Allergic diseases Animals Biological and medical sciences Chi-Square Distribution Desensitization, Immunologic Dose-Response Relationship, Immunologic extracts human health and safety Humans Hymenoptera Hymenoptera - immunology immunology Immunopathology immunotherapy Insect Bites and Stings Insect Bites and Stings - therapy Medical sciences Skin allergic diseases. Stinging insect allergies Skin Tests therapy venoms Wasp Venoms Wasp Venoms - administration & dosage Wasp Venoms - immunology |
Title | The Hymenoptera venom study III: Safety of venom immunotherapy |
URI | https://dx.doi.org/10.1016/S0091-6749(05)80182-4 https://www.ncbi.nlm.nih.gov/pubmed/2229842 https://www.proquest.com/docview/15877123 https://www.proquest.com/docview/49918586 https://www.proquest.com/docview/80089442 |
Volume | 86 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9NAEF-0ByKI-HVYP848KCgld8lmN5v4IBxyR3vXuxNtsW_LfgXEsylt8qB_vbPZbZOixY-XULJptsxMfzu_2Z0ZhF7mmimwBBZKmZmQKKA7sCriMC4ibZRgWDUtWS4u0-GUnM3orJNxbbNLKnmofvw2r-R_tAr3QK82S_YfNLt5KdyAz6BfuIKG4frXOh5-t_W-FzaReADAVX5zFWMHo9HIsv2VKIw7dOEGv9h8EJ91tbWj2_FMbXuVpS_MtMmcdF_sxuDHpUWARkft-eBJvfxqritRN_s8H9og7NU14GqDvG20dVhLKdzZ-jMfltU-Iy_ymXgdUM3jMGWu8ugaVH19a2c8dLA4ZIyGzDVt8ljJXMsUv-z6sV8Q3QUXPm0mAb87oq9wDisrcAPSLmPrrfvLK346HY_55GQ2uYn2MNAH3EN7x-cfP5-35ZiTzBEj_9Y2t-uonep1RN_4abZclTsLsQLBF67zyW5q0rgok3vortdgcOwM5T66YeYP0K0Lf3riIXoH9hJ07CVoTCJo7CUAe3kbOGsJysIPbVnLIzQ9PZm8H4a-f0ZocJpXoTZJKiVAuslymgihtFbYGCnSXOYFIbiICkFFzMB70XlOYq3AuWM2NG6oBh6wj3rzcm4eo0AmBfD2ArxLRYlMqCAGkF5nWCW2X0DaR9laPty7bs4l46BH3p4kBNFyK1oeUd6IlpM-OtiSJ1-4Misc1gagDxj30Yu1gDlgn93QEnNT1ise04zZH7_7CeDz4JBm6e4ngDBlOciij_ad7jbz2073GcFP_vjyp-h2-794hnrVsjbPwVWt5IG3u5_XLZAI |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Hymenoptera+venom+study+III%3A+safety+of+venom+immunotherapy&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Lockey%2C+R+F&rft.au=Turkeltaub%2C+P+C&rft.au=Olive%2C+E+S&rft.au=Hubbard%2C+J+M&rft.date=1990-11-01&rft.issn=0091-6749&rft.volume=86&rft.issue=5+p.775-780&rft.spage=775&rft.epage=780&rft_id=info:doi/10.1016%2FS0091-6749%2805%2980182-4&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon |